Lytix Biopharma AS (DE:6BG) has released an update.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Lytix Biopharma, a Norwegian company focused on cancer treatment, is poised to benefit from its licensing agreement with Verrica Pharmaceuticals, which is working on advancing LTX-35 in cancer treatment. With Dr. Jayson Rieger now leading Verrica and also serving on Lytix’s board, the collaboration could enhance Lytix’s financial prospects, including potential milestone payments and royalties.
For further insights into DE:6BG stock, check out TipRanks’ Stock Analysis page.
